Advancing Ex Vivo Primed Treg Therapies for Neuroinflammatory Disease & Immune Tolerance Restoration

9:30 am - Thursday 25th March 2027

  • Engineering ex vivo primed Tregs with enhanced CNS homing characteristics to improve tissue-specific immune regulation
  • Reviewing clinical learnings from ALS-focused Treg programs to assess opportunities for durable immune tolerance in neuroinflammatory disease
  • Exploring how CNS-targeted Treg development strategies can inform broader applications across autoimmune and inflammatory indications such as aplastic anemia

Speakers:

Vice President - Operations & CMC
Cellenkos